Background: Pharmaceutical companies spend large amounts of money promoting their products to physicians. There is evidence that physicians' interactions with pharmaceutical companies negatively affect their prescribing patterns. The objective of this study was to systematically review the extent of the relationship between physicians and pharmaceutical companies in low-and middle-income countries (LMICs). Methods: Studies assessing the extent of any type of interaction between practicing physicians and pharmaceutical companies were eligible. We searched MEDLINE and EMBASE databases in July 2016. Reviewers worked in duplicate and independently to complete study selection, data abstraction and assessment of methodological features. We summarized the findings narratively. Results: We included 11 eligible studies (7 quantitative and 4 qualitative). Quantitative studies found that pharmaceutical company representatives visited at least 90% of physicians. Printed material, stationery items and drug samples were the most frequently received gifts. Two of the studies assessing direct payment found percentages of 16 and 5%, respectively. Findings of qualitative studies were consistent with those of quantitative studies. In addition, they revealed an increasing tendency for pharmaceutical companies to provide expensive personal gifts, sponsor social events and offer cash as inducements to physicians based on their demands. They also identified building personal relationships, creating a sense of indebtedness and emotional blackmailing as commonly used techniques to influence physicians. Conclusion: A relatively high percentage of physicians in LMICs interact with pharmaceutical companies. Findings have implications for policy and practice, given the current extent of interaction is likely affecting the prescribing habits and professional behaviour of physicians.
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Introduction

P
harmaceutical companies use different approaches to promote their products to physicians. These could be seemingly trivial, such as the ubiquitous dispensing of pens and pads with drug names inscribed. They can also be much more troubling, such as ghost-writing of articles for academic physicians, the payment of large honoraria and consulting fees and the support of lavish trips and entertainment. 1 There is evidence that physicians' interactions with pharmaceutical companies can lead to conflict of interest 2 and decrease public trust in physicians and healthcare system. 3 Importantly, such interactions are strongly associated with inappropriately increased prescribing rates, lower prescribing quality and increased prescribing costs. 4 A number of studies have assessed the extent of interaction between physicians and pharmaceutical companies. In the USA, 84% of physicians reported some form of relationship with the pharmaceutical or medical device industries in 2009. 5 In Libya, 94% physicians reported received at least one visit in the preceding year. 6 In a recent systematic review examining the views and attitudes of physicians towards such interactions, we found that physicians perceived the impact of interactions on prescription behaviour to be minor, particularly when asked about their own behaviour. 7 The regulatory environment in low-and middle-income countries (LMICs) is likely to be less restrictive than that of high-income countries. For instance, while the US' Physician Payments Sunshine Act 8 and the Australian Pharmaceutical Manufacturers Association code of conduct in Australia 9 have been highly publicized, we are not aware of similar initiatives in LMIC. Such regulatory differences would likely lead to different patterns of interactions between physicians and pharmaceutical companies in highincome countries and LMICs.
The objective of this study was to systematically review the literature on the extent (type and frequency) of the relationship between physicians and pharmaceutical companies in LMICs.
Methods
We followed the same methodology described in the protocol of a related published systematic review on association between physicians' interaction with pharmaceutical companies and their clinical practices.
Eligibility criteria
The inclusion criteria were Type of study design: quantitative design (e.g. survey study) and qualitative design (e.g. focus group, interviews, semi-structured interviews); Types of participants: physicians practicing in LMICs. We used the World Bank income classification of countries' income level 10 ; Types of interactions: any form of interaction between physicians and pharmaceutical or medical device industries (e.g. gifts, meeting with representatives of drug companies or medical/ surgical device manufacturers; receiving free drug samples, industry-provided meals; pharmaceutical-funded research; pharmaceutical-sponsored continuous medical education; consultancy; stock ownership); Types of outcomes: the extent of the interaction between physicians and pharmaceutical companies.
We excluded studies that focus only on resident doctors, patients or general public. We also excluded studies where individual physicians were not the unit of analysis (e.g. study using national level data).
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In addition, we excluded editorials, opinion polls, systematic reviews and studies not published in English language. We did not exclude studies based on date of publication.
Search strategy
We electronically searched the MEDLINE and EMBASE databases using the OVID interface in July 2016. We designed the search strategy with the help of a medical librarian. The strategy combined terms for 'physicians' and 'pharmaceuticals' and used both free text words and medical subject headings. We did not use any search filter (Supplementary file S1). In addition, we reviewed the reference lists of included studies and searched grey literature (theses, conference proceedings and dissertations).
Selection of studies
Teams of two reviewers screened titles and abstracts of identified citations for potential eligibility in duplicate and independently. They then screened in duplicate and independently the full texts of citations judged as potentially eligible by at least one of the two reviewers. We conducted calibration exercises and used a standardized and pilot tested screening form. We resolved disagreements by discussion or with the help of a third reviewer.
Data collection
Teams of two reviewers abstracted data from eligible studies in duplicate and independently. Disagreements were resolved by discussion or with the help of a third reviewer. We conducted calibration exercises and used a standardized and pilot-tested data abstraction form to collect data on the following variables: study design; funding source; characteristics of participants and setting; type of interaction addressed and results.
Assessment of methodological features
Teams of two reviewers assessed the methodological features of each eligible study in duplicate and independently. They resolved disagreements by discussion or with the help of a third reviewer. They assessed the methodological quality of surveys using the following criteria, adapted from one of our previously published systematic review 12 : sample size calculation, reporting of a sampling frame, the sampling method, the response rate and the validity of tool. They assessed the methodology of qualitative studies using the Critical Appraisal Skills Programme (CASP) checklist. 13 
Data analysis and synthesis
We assessed the agreement between reviewers for full-text screening by calculating the kappa statistic. We did not conduct a metaanalysis due to the nature of the data. Instead, we narratively summarized findings, stratified by type of interaction (representative visit vs. gifts) and study design (quantitative vs. qualitative). We also indicated the year of the study for each finding (and if not reported, the publication year). Figure 1 shows the study flow. Of the 12 400 citations identified by the electronic literature search, 12 papers reporting on 11 eligible studies met our inclusion criteria. 6, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] We excluded 50 studies for the following reasons: studies from high-income countries (n = 34), studies where practicing physicians were not the unit of analysis (n = 2), studies that did not report on the outcome of interest (n = 4), not original studies (n = 7), not in English (n = 2) and only abstract (n = 1).The kappa statistic value for full-text screening was 0.78, suggesting high levels of agreement.
Results
Included studies
Characteristics of included studies
Supplementary file S2 shows the characteristics of the 11 included studies. The sample size in those studies varied between 3 and 2235 physicians. The countries where the studies were conducted included Brazil (n = 1), 21 Turkey (n = 2), 17, 18 Bangladesh (n = 2), 19,25 India (n = 2), 20 Libya (n = 1), 6, 15 Yemen (n = 1), 14 South Africa (n = 1) 22 and Peru (n = 1). 23 The publication years of the included studies ranged from 1999 to 2015. Of the 11 studies, 7 were quantitative and 4 were qualitative. 15, 17, 20, 25 One of the qualitative studies reported quantitative data. 14 Table 1 shows the methodological assessment of the quantitative studies while Supplementary file S3 shows the methodological assessment of the qualitative studies. Only three studies reported on their sources of funding, which were respectively the Ministry of Health, 21 the WHO-India office 20 and the Swedish International Development Agency. 25 Although the majority of quantitative studies described their sampling frame, fewer fulfilled the following factors related to risk of bias: using random approach to sampling (n = 3); 6, 18, 19 reporting pilot-testing tools (n = 1) 23 and reporting using validated tools (n = 1). 23 The majority of studies failed to report their response rate. Also, in one study, the sample size was low (3 physicians). 22 The four qualitative studies met most of the items of the CASP tool checklist, except the following: adequate consideration of relationship between researcher and participants (n = 1), 17 and rigorous data analysis (n = 2).
Methodological assessment of included studies
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Summary of findings
Extent of interactions
Five studies reported quantitative data on the extent of interactions:
Seidel documented the interaction of pharmaceutical representatives with members of a three-doctor urban general practice in South Africa in 1999. The study found that the three physicians in South Africa had an average 7.4 visits by medical representative per week and 3.5 min per visit over 35 contact weeks. 22 Güldal and S°min 18 conducted a survey in 2000 which indicated that 90% of physicians in Turkey were visited by pharmaceutical company representatives at least once per week. Alssageer and Kowalski 6, 15 reported in 2012 that 94% of physicians in public and private practices in Libya received at least one visit in the preceding year. De Ferrari et al. 23 found that 95% of attending physicians in a public general hospital in Peru reported ongoing encounters with pharmaceutical representatives in 2013. Al-Areefi et al. conducted a qualitative study to assess the perception of physicians in Sana'a, Yemen regarding medical representative visits. The investigators reported that only 1 out of 32 participants (3%) never received a visit from a medical representative during a time frame of three months in 2013. 14 
Types of gifts received
Six quantitative studies and 3 qualitative studies assessed the types of gifts received. Table 2 summarizes the findings of the quantitative studies. Overall, printed material, stationery items and drug samples were the most frequently received gifts. Only two studies assessed direct payment with reported percentages of 16 and 5%, respectively. 6, 19 The findings of the qualitative studies are presented later:
Roy et al. 20 conducted interviews and focus groups with doctors, senior executives, chemists and medical representatives in India in 2003. They found that gifts of high values such as electronics and jewellery are replacing the brand-reminder items such as pens. They also found that pharmaceutical companies financed educational programmes and conferences. Mohiuddin et al. conducted in-depth interviews, observations and round table discussion with physicians, village doctors, representatives from drug administration and executives of pharmaceutical companies in Bangladesh in 2009. Although the most commonly offered items were brand-reminders such as drug samples, writing pads, pens and literature on drugs, there was an increasing tendency to provide almost everything as gifts to physicians based on their demands. These included pleasure trips with family and friends; home; car; cash or sponsorship for personal programmes such as wedding and birthday; decoration for home and internet modem. 25 Civaner et al. conducted a study in 2012 where they interviewed physicians and company employees in Turkey. They reported a range of gift-giving activities including brand-reminder items (such as meals for the promotion of a specific drug, free samples, journal ads, meetings and trips), financial supports for healthcare services (such as establishing a clinic, providing medical equipment and devices to clinics and buying office supplies) and provision of personal financial interest for increasing sales. They also reported creating social opportunities to fulfil physician need to gather with friends, rest or have a holiday, though to a lesser extent. 17 
Marketing techniques
In India, a study conducted in 2003 reported that pharmaceutical companies used misleading information, incentives and unethical trade practices. Some physicians also demanded incentives as well as threatened to boycott companies that did not comply with their demands for sponsorship. 20 In Bangladesh, a study conducted in 2009 found that pharmaceutical companies used a range of marketing techniques including gift-giving, persuasion, inducements, emotional blackmailing, support to family members and support in times of personal emergencies. Physicians also engaged in such interactions according to their particular needs and interests. 25 In Turkey, a study conducted in 2012 reported that pharmaceutical companies relied on building personal relationships, exerting a subtle influence and creating a sense of indebtedness to persuade physicians. 17 
Discussion
We aimed to systematically review the literature on the extent of the relationship between physicians and pharmaceutical companies in LMICs. We identified 11 eligible studies, each of which had a number of methodological limitations. Overall, we found that pharmaceutical company representatives visited at least 90% of physicians, while printed material, stationery items and drug samples were the most frequent types of gifts. In two studies, 16 and 5% of physicians reported receiving direct payments. The qualitative studies revealed an increasing tendency for pharmaceutical companies to provide expensive personal gifts, sponsor social events and offer direct cash payments as inducements to physicians based on their demands. Across studies, pharmaceutical companies utilized a range of strategies to influence prescribers, including building personal relationships, giving gifts, inducements, creating a sense of indebtedness and emotional blackmailing. Pharmaceutical companies and physicians seem to engage in the interactions according to their particular needs and interests. The major strength of the study is the use of standard systematic review methodology. In addition, this is the first systematic review that focuses on the nature and extent of the relationship between physicians and pharmaceutical companies in LMICs. The main limitation of this review relates to the methodological weaknesses of the included primary studies (e.g. use of convenience sample, use of non-validated questionnaires, low response rates). Also, the findings from some of the older studies might not reflect current interactions between physicians and pharmaceutical companies. Furthermore, the findings may not be applicable to residents and physicians in training as those may be subjected to different regulatory measures compared with practicing physicians.
Pharmaceutical companies seem to implement classical marketing theories, such as 'assessing candidates' profiles', 'evaluating candidates' needs' and 'focusing on customer satisfaction' to remain competitive and maximize their influence. 17, 26 These are reflected in reported activities such as: 'history taking' of physicians' interests, preferences and lifestyle details; monitoring of prescriptions; establishing training curriculum for medical representatives on how to cater to identified needs and demands of physicians (expressed or otherwise) and cultivating popular physicians to establish brand loyalty and fulfil individual and company targets. 17, 25 Several studies on the extent of relationship of physicians with the pharmaceutical companies have been conducted in high-income countries. Overall, there seems to be a decreasing trend in industry interaction with physicians, particularly in the USA. This is further reflected by a decline of 10.3% in promotion expenditure in North America compared with an increase of 5.6% in Latin America and Asia Pacific in 2010. 27 A national survey conducted in the USA found that the prevalence of self-reported physicianindustry relationships has decreased significantly overall from 94% in 2004 to 84% in 2009. Specifically, the number of physicians reporting receiving drug samples decreased from 78 to 64%, while those reporting receiving any gifts decreased from 83 to 71%. 5 Another US cross-sectional study spanning the period of 2001-10 found that provider-targeted promotion of drugs was declining in 2010, after a peak in 2004. 28 Similarly, the percentages of family medicine residencies in the USA having no interactions with the pharmaceutical industry increased dramatically from 26% in 2008 to 49% in 2013. 29 In Australia, 66-79% of offers by pharmaceutical companies were accepted by physicians, with lower percentages reported for sponsored symposia (53%), invitations to product launches (49%) and travel that included partners (27%). Most of the gifts and requests for support complied with professional and pharmaceutical industry guidelines. 30 These decreases have likely resulted from initiatives in highincome countries to manage physician-industry relationships. For instance, teaching hospitals and medical schools are increasingly implementing new policies that prohibit certain types of interactions (e.g. drug samples and industry-sponsored meals), limiting representatives' access to physicians and banning faculty participation in speaker bureaus. 31, 32 Scores of academics (which reflect strictness of policies addressing physician-industry interactions) have further prompted reform in this area. 33 On the legal front, the US Physician Payments Sunshine Act implemented in 2010 calls for drug and medical equipment manufacturers whose products are covered by federal insurance programmes to report financial transactions made to doctors or teaching hospitals. 8 In 2016, Medicines Australia revised its code of conduct, requiring pharmaceutical companies to publicly disclose payments to health professionals for their services, educational grants and sponsorships to attend educational events. 9 We are not aware of similar initiatives in LMICs. In fact, a number of the included studies in this review attributed the high rates of interactions to the absence or poor enforcement of measures to regulate marketing practices for pharmaceuticals. In Libya, there was a lack of legal statutes to direct appropriate promotional activities, reliable independent drug information or any educational activities related to rational use of medicines in the website of the Libyan Board of Medical Specialities. 15 In Brazil, initiatives targeting regulation of physician-industry interactions were still taking shape, with the existing medical ethics code perceived as insufficient and requiring enhancement to ensure high ethical standards. 21 In Bangladesh, the existing code of marketing practices for pharmaceuticals was poorly enforced with no efforts from regulators to disseminate this information to medical representatives and physicians. This was coupled to the complete absence of physicians' professional bodies to oversee professional conducts of its members. 25 
Implications for policy and practice
The findings of this review have implications for policy and practice, given the current extent of physician-industry interaction is likely affecting the prescribing habits and professional behaviour of physicians. 4 Restricting physician-industry interactions could be one potentially effective option to consider, particularly in light of the evidence that restriction policies may improve prescribing behaviours. 34 This could be achieved at the governmental level through legislations specifying the types of interactions that are allowed (and those that are not), and institutional level by restricting promotional materials and representative visits at healthcare organizations. 35 Such policies are likely to be acceptable in light of research showing that the majority of physicians in LMICs supported policies that restrict physicians' interactions with pharmaceutical representatives. 7 Additionally, given that patients express a desire to be informed about these relationships, 12 considerations could be given to establishing national disclosure systems of physician-industry relationships. 36 This could also help capture physician-industry relationships in non-institutional settings. However, the literature on public disclosure of payments to physicians from industry is still in its infancy. 36 Regulatory measures should be complemented by efforts to address the information need of prescribers. 17 Establishing independent sources of information, e.g. academic detailing, 37 mitigating industry involvement in continuing medical education 38 and creating a national medicine list for reimbursement policies could help reduce reliance on pharmaceutical companies as the main source of information regarding drug use. In the absence of such initiatives, pharmaceutical companies will continue to exploit gaps in prescribers' needs to fulfil their own interests, and the problems related to marketing practices will persist. 17 Finally, given that prescribing habits are largely shaped during medical training, medical schools could consider establishing strong pharmaceutical conflict of interest policies. 39 Education about how to identify, evaluate and manage potential conflicts could also be provided in medical schools. 40 
Implications for research
The findings of this systematic review suggest the need for more research in LMICs. Furthermore, it would be important to develop the survey questionnaires based on qualitative local data. This is because the questionnaires in the included studies were apparently based on surveys from high-income countries. Those would have missed types of interactions specific to the local context. Only locally conducted qualitative studies would allow uncovering such interactions and ensuring they are assessed in surveys. Additional studies are also required to assess physicians' degree of compliance with national regulations.
Future systematic reviews could also examine the extent of interactions of residents, physicians in training and other allied healthcare professionals with pharmaceutical companies and explore how they differ from those of practicing physicians.
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Key points
Pharmaceutical company representatives visited at least 90% of physicians in low-and middle-income countries (LMICs). Printed material, stationery items and drug samples were the most frequently received gifts. Pharmaceutical companies used inducements, gift-giving, building personal relationships, creating a sense of indebtedness and emotional blackmailing to influence physician prescribing behaviours. Regulating physicians' interactions with pharmaceutical companies is necessary in LMICs, given the current extent of interactions.
